These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36719467)

  • 21. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
    Oyarzun P; Kashyap M; Fica V; Salas-Burgos A; Gonzalez-Galarza FF; McCabe A; Jones AR; Middleton D; Kobe B
    Front Immunol; 2021; 12():598778. PubMed ID: 33717077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel vaccine based on SARS-CoV-2 CD4
    Palatnik-de-Sousa I; Wallace ZS; Cavalcante SC; Ribeiro MPF; Silva JABM; Cavalcante RC; Scheuermann RH; Palatnik-de-Sousa CB
    Sci Rep; 2022 Oct; 12(1):16731. PubMed ID: 36202985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.
    Johansson AM; Malhotra U; Kim YG; Gomez R; Krist MP; Wald A; Koelle DM; Kwok WW
    PLoS Pathog; 2021 Dec; 17(12):e1010203. PubMed ID: 34965282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8
    Qiu C; Xiao C; Wang Z; Zhu G; Mao L; Chen X; Gao L; Deng J; Su J; Su H; Fang EF; Zhang ZJ; Zhang J; Xie C; Yuan J; Luo OJ; Huang LA; Wang P; Chen G
    Front Immunol; 2021; 12():764949. PubMed ID: 35116022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoinformatic paradigm predicts macrophage and T-cells epitope responses against globally conserved spike fragments of SARS CoV-2 for universal vaccination.
    Maiti S; Banerjee A; Santra D; Kanwar M
    Int Immunopharmacol; 2022 Jul; 108():108847. PubMed ID: 35597120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals.
    Lang-Meli J; Luxenburger H; Wild K; Karl V; Oberhardt V; Salimi Alizei E; Graeser A; Reinscheid M; Roehlen N; Reeg DB; Giese S; Ciminski K; Götz V; August D; Rieg S; Waller CF; Wengenmayer T; Staudacher D; Huzly D; Bengsch B; Kochs G; Schwemmle M; Emmerich F; Boettler T; Thimme R; Hofmann M; Neumann-Haefelin C
    Nat Microbiol; 2022 May; 7(5):675-679. PubMed ID: 35484232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.
    Garcia-Valtanen P; Hope CM; Masavuli MG; Yeow AEL; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Bouras G; Gummow J; Ferguson C; O'Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Kok-Lim C; Beard MR; Weiskopf D; Sette A; Turville SG; Bull RA; Barry SC; Grubor-Bauk B
    Cell Rep Med; 2022 Jun; 3(6):100651. PubMed ID: 35654046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-Protection Induced by Highly Conserved Human B, CD4
    Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzler B; Amin M; Chilukuri A; Edwards RA; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
    bioRxiv; 2023 May; ():. PubMed ID: 37292861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86.
    Sette A; Sidney J; Grifoni A
    Cell Host Microbe; 2024 Jan; 32(1):19-24.e2. PubMed ID: 38070502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals.
    Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AA
    bioRxiv; 2021 Dec; ():. PubMed ID: 34909772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity.
    Riou C; Keeton R; Moyo-Gwete T; Hermanus T; Kgagudi P; Baguma R; Valley-Omar Z; Smith M; Tegally H; Doolabh D; Iranzadeh A; Tyers L; Mutavhatsindi H; Tincho MB; Benede N; Marais G; Chinhoyi LR; Mennen M; Skelem S; du Bruyn E; Stek C; ; de Oliveira T; Williamson C; Moore PL; Wilkinson RJ; Ntusi NAB; Burgers WA
    Sci Transl Med; 2022 Feb; 14(631):eabj6824. PubMed ID: 34931886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron.
    Mazzoni A; Vanni A; Spinicci M; Capone M; Lamacchia G; Salvati L; Coppi M; Antonelli A; Carnasciali A; Farahvachi P; Giovacchini N; Aiezza N; Malentacchi F; Zammarchi L; Liotta F; Rossolini GM; Bartoloni A; Cosmi L; Maggi L; Annunziato F
    Front Immunol; 2022; 13():801431. PubMed ID: 35154116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
    Prakash S; Dhanushkodi NR; Singer M; Quadiri A; Zayou L; Vahed H; Coulon PG; Ibraim IC; Tafoya C; Hitchcock L; Landucci G; Forthal DN; El Babsiri A; Tifrea DF; Figueroa CJ; Nesburn AB; Kuppermann BD; Gil D; Jones TM; Ulmer JB; BenMohamed L
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention.
    Guo E; Guo H
    PLoS One; 2020; 15(12):e0239566. PubMed ID: 33301503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4
    Chen Y; Mason GH; Scourfield DO; Greenshields-Watson A; Haigh TA; Sewell AK; Long HM; Gallimore AM; Rizkallah P; MacLachlan BJ; Godkin A
    Cell Rep; 2023 Aug; 42(8):112827. PubMed ID: 37471227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics-based SARS-CoV-2 epitopes design and the impact of spike protein mutants on epitope humoral immunities.
    Sun Q; Huang Z; Yang S; Li Y; Ma Y; Yang F; Zhang Y; Xu F
    Immunobiology; 2022 Nov; 227(6):152287. PubMed ID: 36244092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.
    Khan K; Khan SA; Jalal K; Ul-Haq Z; Uddin R
    Virology; 2022 Jul; 572():28-43. PubMed ID: 35576833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.